Please ensure Javascript is enabled for purposes of website accessibility

Why Ionis Pharmaceuticals Inc Couldn't Hold Its Price Today

By Brian Orelli, PhD - Apr 7, 2016 at 1:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An FDA clinical hold, oh my.

Image source: Ionis Pharmaceuticals.

What: Ionis Pharmaceuticals (IONS 0.23%) was down as much as 13% today, although it's pulled back a bit in midday trading after announcing that the Food and Drug Administration put a clinical hold on a clinical trial, dubbed CARDIO-TTR, being run by its partner, GlaxoSmithKline (GSK 0.02%).

So what: Clinical holds are usually really bad news because the FDA usually issues them when it's worried about the safety of a drug.

In this case, though, the phase 3 clinical trial testing IONIS-TTRRX in patients with transthyretin (TTR) amyloid cardiomyopathy hadn't started yet, so the clinical hold appears to just be precautionary while the FDA waits for GlaxoSmithKline to answer its questions.

Ionis is currently running another phase 3 trial, NEURO-TTR, testing the drug in patients with a related disease, TTR familial amyloid polyneuropathy, which affects the nervous system rather than the heart. The FDA hasn't put that trial on a hold, so the issue appears to be disease specific -- patients with the cardiomyopathy version are sicker than those with the polyneuropathy version.

Now what: Worst-case scenario, the FDA won't let Ionis and GlaxoSmithKline test IONIS-TTRRX for the cardiomyopathy version. Best-case scenario, the FDA just wants more monitoring of patients, and GlaxoSmithKline only needs to adjust the clinical trial protocol to convince the FDA that patients will be well monitored in case issues arise.

It may be a few months before investors know whether IONIS-TTRRX is alive or dead as a treatment for TTR amyloid cardiomyopathy. Unfortunately, the delay allows the duo's competitor, Alnylam Pharmaceuticals, to get further ahead with its already-started phase 3 clinical trial testing revusiran in TTR amyloid cardiomyopathy -- that one is scheduled to read out in early 2019.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
$43.70 (0.02%) $0.01
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
$39.34 (0.23%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.